Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease: A randomised controlled trial

Gut

Volumn 66, Issue 11, 2017, Pages 1918-1925

  Allez, Matthieu ^a   Skolnick, Brett E ^b   Wisniewska Jarosinska, Maria ^c   Petryka, Robert ^d   Overgaard, Rune Viig ^e  

^a SAINT LOUIS HOSPITAL   (France)

^b NOVO NORDISK INC   (United States)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d NZOZ Centrum Medyczne   (Poland)

^e NOVO NORDISK A S   (Denmark)

Author keywords

Crohn'S DISEASE

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AMINOSALICYLIC ACID; C REACTIVE PROTEIN; CALGRANULIN; CORTICOSTEROID; IMMUNOGLOBULIN G4; METHOTREXATE; MONOCLONAL ANTIBODY; NNC 0142 0002; PLACEBO; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; NNC0142-0002 MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ENDOSCOPY; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOGENICITY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; ADOLESCENT; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FOLLOW UP; IMMUNOLOGY; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84982859311     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-311824     Document Type: Article

References (21)

1. Baumgart DC, Sandborn WJ. Crohns disease. Lancet 2012;380:1590-605.
2. Mayer L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol 2010;45:9-16.
3. Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohns disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010;31:92-101.
4. Allez M, Mayer L. Regulatory T cells: Peace keepers in the gut. Inflamm Bowel Dis 2004;10:666-76.
5. Croitoru K, Zhou P. T-cell-induced mucosal damage in the intestine. Curr Opin Gastroenterol 2004;20:581-6.
6. Neurath MF, Finotto S, Fuss I, et al. Regulation of T-cell apoptosis in inflammatory bowel disease: To die or not to die, that is the mucosal question. Trends Immunol 2001;22:21-6.
7. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010;235:267-85.
8. Jamieson AM, Diefenbach A, McMahon CW, et al. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002;17:19-29.
9. Groh V, Bahram S, Bauer S, et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996;93:12445-50.
10. Allez M, Tieng V, Nakazawa A, et al. CD4+NKG2D+ T cells in Crohns disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology 2007;132:2346-58.
11. La Scaleia R, Stoppacciaro A, Oliva S, et al. NKG2D/Ligand dysregulation and functional alteration of innate immunity cell populations in pediatric IBD. Inflamm Bowel Dis 2012;18:1910-22.
12. Tieng V, Le Bouguénec C, du Merle L, et al. Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. Proc Natl Acad Sci USA 2002;99:2977-82.
13. Pariente B, Mocan I, Camus M, et al. Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4+ T cells of patients with Crohns disease. Gastroenterology 2011;141:217-26, 226.e1-2.
14. Camus M, Esses S, Pariente B, et al. Oligoclonal expansions of mucosal T cells in Crohns disease predominate in NKG2D-expressing CD4 T cells. Mucosal Immunol 2014;7:325-34.
15. Kjellev S, Haase C, Lundsgaard D, et al. Inhibition of NKG2D receptor function by antibody therapy attenuates transfer-induced colitis in SCID mice. Eur J Immunol 2007;37:1397-406.
16. Ito Y, Kanai T, Totsuka T, et al. Blockade of NKG2D signaling prevents the development of murine CD4+ T cell-mediated colitis. Am J Physiol Gastrointest Liver Physiol 2008;294:G199-207.
17. Höe S, Mention JJ, Monteiro RC, et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004;21:367-77.
18. Meresse B, Chen Z, Ciszewski C, et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-Activated killer cells in celiac disease. Immunity 2004;21:357-66.
19. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohns disease activity index. National Cooperative Crohns Disease Study. Gastroenterology 1976;70:439-44.
20. Kleinschek MA, Boniface K, Sadekova S, et al. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med 2009;206:525-34.
21. Hershberg RM, Mayer LF. Antigen processing and presentation by intestinal epithelial cells-polarity and complexity. Immunol Today 2000;21:123-8.